Literature DB >> 16390330

The allosteric enhancer PD81,723 increases chimaeric A1/A2A adenosine receptor coupling with Gs.

Samita Bhattacharya1, Rebecca L Youkey, Kobina Ghartey, Matthew Leonard, Joel Linden, Amy L Tucker.   

Abstract

PD81,723 {(2-amino-4,5-dimethyl-3-thienyl)-[3-(trifluromethyl)-phenyl]methanone} is a selective allosteric enhancer of the G(i)-coupled A1 AR (adenosine receptor) that is without effect on G(s)-coupled A2A ARs. PD81,723 elicits a decrease in the dissociation kinetics of A1 AR agonist radioligands and an increase in functional agonist potency. In the present study, we sought to determine whether enhancer sensitivity is dependent on coupling domains or G-protein specificity of the A1 AR. Using six chimaeric A1/A2A ARs, we show that the allosteric effect of PD81,723 is maintained in a chimaera in which the predominant G-protein-coupling domain of the A1 receptor, the 3ICL (third intracellular loop), is replaced with A2A sequence. These chimaeric receptors are dually coupled with G(s) and G(i), and PD81,723 increases the potency of N6-cyclopentyladenosine to augment cAMP accumulation with or without pretreatment of cells with pertussis toxin. Thus PD81,723 has similar functional effects on chimaeric receptors with A1 transmembrane sequences that couple with G(i) or G(s). This is the first demonstration that an allosteric regulator can function in the context of a switch in G-protein-coupling specificity. There is no enhancement by PD81,723 of G(i)-coupled A2A chimaeric receptors with A1 sequence replacing A2A sequence in the 3ICL. The results suggest that the recognition site for PD81,723 is on the A1 receptor and that the enhancer acts to directly stabilize the receptor to a conformational state capable of coupling with G(i) or G(s).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16390330      PMCID: PMC1449996          DOI: 10.1042/BJ20051422

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

1.  Dominance of G(s) in doubly G(s)/G(i)-coupled chimaeric A(1)/A(2A) adenosine receptors in HEK-293 cells.

Authors:  A L Tucker; L G Jia; D Holeton; A J Taylor; J Linden
Journal:  Biochem J       Date:  2000-11-15       Impact factor: 3.857

2.  Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor.

Authors:  Zhan-Guo Gao; Aishe Chen; Dov Barak; Soo-Kyung Kim; Christa E Müller; Kenneth A Jacobson
Journal:  J Biol Chem       Date:  2002-03-12       Impact factor: 5.157

Review 3.  G protein-coupled receptor allosterism and complexing.

Authors:  Arthur Christopoulos; Terry Kenakin
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

4.  Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives.

Authors:  Z G Gao; J E Van Muijlwijk-Koezen; A Chen; C E Müller; A P Ijzerman; K A Jacobson
Journal:  Mol Pharmacol       Date:  2001-11       Impact factor: 4.436

5.  Human A(2A) adenosine receptors: high-affinity agonist binding to receptor-G protein complexes containing Gbeta(4).

Authors:  Lauren J Murphree; Melissa A Marshall; Jayson M Rieger; Timothy L MacDonald; Joel Linden
Journal:  Mol Pharmacol       Date:  2002-02       Impact factor: 4.436

6.  Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl) phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor.

Authors:  A Kourounakis; C Visser; M de Groote; A P IJzerman
Journal:  Biochem Pharmacol       Date:  2001-01-15       Impact factor: 5.858

Review 7.  Galantamine for Alzheimer's disease.

Authors:  J Olin; L Schneider
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 8.  Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection.

Authors:  J Linden
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

9.  Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions.

Authors:  Z G Gao; A P Ijzerman
Journal:  Biochem Pharmacol       Date:  2000-09-01       Impact factor: 5.858

10.  Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives.

Authors:  Zhan-Guo Gao; Seong Gon Kim; Kelly A Soltysiak; Neli Melman; Adriaan P IJzerman; Kenneth A Jacobson
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

View more
  6 in total

1.  The second extracellular loop of the adenosine A1 receptor mediates activity of allosteric enhancers.

Authors:  Dylan P Kennedy; Fiona M McRobb; Susan A Leonhardt; Michael Purdy; Heidi Figler; Melissa A Marshall; Mahendra Chordia; Robert Figler; Joel Linden; Ruben Abagyan; Mark Yeager
Journal:  Mol Pharmacol       Date:  2013-11-11       Impact factor: 4.436

Review 2.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

Review 3.  Allosteric modulation of purine and pyrimidine receptors.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao; Anikó Göblyös; Adriaan P Ijzerman
Journal:  Adv Pharmacol       Date:  2011

4.  Functional Expression of Adenosine A3 Receptor in Yeast Utilizing a Chimera with the A2AR C-Terminus.

Authors:  Abhinav R Jain; Anne S Robinson
Journal:  Int J Mol Sci       Date:  2020-06-26       Impact factor: 5.923

Review 5.  Allosteric Modulation of Adenosine A2A Receptors as a New Therapeutic Avenue.

Authors:  Mustafa Korkutata; Lokesh Agrawal; Michael Lazarus
Journal:  Int J Mol Sci       Date:  2022-02-14       Impact factor: 5.923

6.  Allosteric modulation of adenosine receptors.

Authors:  Anikó Göblyös; Ad P Ijzerman
Journal:  Purinergic Signal       Date:  2008-07-10       Impact factor: 3.765

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.